Hong Sang

Array ( [id] => 18102463 [patent_doc_number] => 11542339 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => Anti-CD43 antibody and use thereof for cancer treatment [patent_app_type] => utility [patent_app_number] => 16/871280 [patent_app_country] => US [patent_app_date] => 2020-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 60 [patent_no_of_words] => 30470 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16871280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18748386 [patent_doc_number] => 11807682 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-07 [patent_title] => M971 chimeric antigen receptors [patent_app_type] => utility [patent_app_number] => 16/869792 [patent_app_country] => US [patent_app_date] => 2020-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 13790 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16869792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20187262 [patent_doc_number] => 12398369 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-26 [patent_title] => Purified double negative T cell and preparation and use thereof [patent_app_type] => utility [patent_app_number] => 17/616755 [patent_app_country] => US [patent_app_date] => 2020-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 16 [patent_no_of_words] => 1095 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16399086 [patent_doc_number] => 20200339944 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => METHODS OF MANUFACTURING ALLOGENEIC CAR T CELLS [patent_app_type] => utility [patent_app_number] => 16/857394 [patent_app_country] => US [patent_app_date] => 2020-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24215 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16857394 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16444916 [patent_doc_number] => 10836828 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-17 [patent_title] => Anti-TREM1 antibodies and related methods [patent_app_type] => utility [patent_app_number] => 16/852294 [patent_app_country] => US [patent_app_date] => 2020-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 110 [patent_no_of_words] => 53107 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16852294 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16282705 [patent_doc_number] => 20200276307 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => Anti-ErbB3 Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/848752 [patent_app_country] => US [patent_app_date] => 2020-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18163 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16848752 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17113222 [patent_doc_number] => 20210293819 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => METHOD FOR IDENTIFYING CANCER-SPECIFIC ANTIBODIES UTILIZING IMMUNE CHECKPOINT INHIBITION [patent_app_type] => utility [patent_app_number] => 16/822307 [patent_app_country] => US [patent_app_date] => 2020-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8535 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 300 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16822307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18590253 [patent_doc_number] => 11739136 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-29 [patent_title] => Inducible dominant negative PD-1 and uses in adoptive cell therapy [patent_app_type] => utility [patent_app_number] => 16/822497 [patent_app_country] => US [patent_app_date] => 2020-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 25567 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16822497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16361018 [patent_doc_number] => 20200317769 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 16/821287 [patent_app_country] => US [patent_app_date] => 2020-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40692 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 258 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16821287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20302451 [patent_doc_number] => 12448429 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-21 [patent_title] => T cell receptors specific to b-cell maturation antigen for treatment of cancer [patent_app_type] => utility [patent_app_number] => 17/430938 [patent_app_country] => US [patent_app_date] => 2020-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 69 [patent_no_of_words] => 27465 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 315 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17430938 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17580199 [patent_doc_number] => 20220137054 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => NEW BIOMARKERS AND BIOTARGETS IN RENAL CELL CARCINOMA [patent_app_type] => utility [patent_app_number] => 17/434225 [patent_app_country] => US [patent_app_date] => 2020-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14276 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17434225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16282636 [patent_doc_number] => 20200276238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => CHIMERIC CYTOKINE RECEPTORS BEARING A PD-1 ECTODOMAIN [patent_app_type] => utility [patent_app_number] => 16/804545 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20248 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16804545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18328258 [patent_doc_number] => 11633475 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-25 [patent_title] => Human anti-VEGFR-2/KDR antibodies [patent_app_type] => utility [patent_app_number] => 16/799977 [patent_app_country] => US [patent_app_date] => 2020-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 23 [patent_no_of_words] => 10280 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16799977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16267360 [patent_doc_number] => 20200268847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => Methods of Treating Newly Diagnosed Multiple Myeloma with a Combination of An Antibody that Specifically Binds CD38, Lenalidomide and Dexamethasone [patent_app_type] => utility [patent_app_number] => 16/797301 [patent_app_country] => US [patent_app_date] => 2020-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21524 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -189 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16797301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18717887 [patent_doc_number] => 11795218 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-24 [patent_title] => Diagnosis and therapy of cancer involving cancer stem cells [patent_app_type] => utility [patent_app_number] => 16/795468 [patent_app_country] => US [patent_app_date] => 2020-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 23 [patent_no_of_words] => 39841 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 257 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16795468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16377501 [patent_doc_number] => 20200326343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => GENE AND ITS EXPRESSION PRODUCT PROMOTING THE OCCURRENCE AND DEVELOPMENT OF CANCER AND APPLICATION [patent_app_type] => utility [patent_app_number] => 16/794240 [patent_app_country] => US [patent_app_date] => 2020-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17346 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16794240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17800205 [patent_doc_number] => 11414486 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-16 [patent_title] => Transgene genetic tags and methods of use [patent_app_type] => utility [patent_app_number] => 16/794673 [patent_app_country] => US [patent_app_date] => 2020-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 22 [patent_no_of_words] => 33133 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16794673 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16376399 [patent_doc_number] => 20200325241 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => NOVEL CHIMERIC ANTIGEN RECEPTORS AND LIBRARIES [patent_app_type] => utility [patent_app_number] => 16/788255 [patent_app_country] => US [patent_app_date] => 2020-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12251 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 1 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16788255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16581515 [patent_doc_number] => 20210015917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => Combination Of The Application Of Antibodies For Immunostimulation Together With Glucocorticoids [patent_app_type] => utility [patent_app_number] => 16/783500 [patent_app_country] => US [patent_app_date] => 2020-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14377 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16783500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19949452 [patent_doc_number] => 12320812 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-03 [patent_title] => Markers for the diagnosis of biochemical recurrence in prostate cancer [patent_app_type] => utility [patent_app_number] => 16/783238 [patent_app_country] => US [patent_app_date] => 2020-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 22 [patent_no_of_words] => 57144 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16783238 [rel_patent_id] =>[rel_patent_doc_number] =>)